Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Sanofi has moved materially closer to Regeneron Pharmaceuticals (NASDAQ), although there is currently no disclosed takeover proposal or confirmed acquisition interest involving the U.S. biotechnology company.</li><li>The latest development is an expanded immunology alliance announced on October 1, under which Sanofi will pay Regeneron $1 billion upfront and potentially another $7 billion tied to development, regulatory and commercial milestones.</li><li>The companies will jointly develop four next-generation Regeneron antibodies, share development and commercialization costs equally, and split future global profits 50-50.</li></ul>

Sanofi has moved materially closer to Regeneron Pharmaceuticals (NASDAQ), although there is currently no disclosed takeover proposal or confirmed acquisition interest involving the U.S. biotechnology company.The latest development is an expanded immunology alliance announced on October 1, under which Sanofi will pay Regeneron $1 billion upfront and potentially another $7 billion tied to development, regulatory and commercial milestones.The companies will jointly develop four next-generation Regeneron antibodies, share development and commercialization costs equally, and split future global profits 50-50.

Sanofi Acquisition Of Regeneron: Could Dupixent & An $8 Billion Alliance Spark A Bigger Deal?

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
 <li>Sanofi is strategically repositioning itself as a pure-play biopharmaceutical company, focusing on high-growth areas like immunology and vaccines, underscored by the planned separation of its consumer healthcare business.</li>
 <li>The company's growth is heavily reliant on its blockbuster drug, Dupixent, which continues to see robust sales growth and label expansions. However, this concentration presents a significant risk ahead of its potential loss of exclusivity post-2031.</li>
 <li>While Sanofi boasts a strong dividend profile and an attractive valuation relative to peers, the company faces challenges including recent pipeline setbacks, increasing competition, and persistent drug pricing pressures in key markets.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Sanofi is strategically repositioning itself as a pure-play biopharmaceutical company, focusing on high-growth areas like immunology and vaccines, underscored by the planned separation of its consumer healthcare business.
  The company's growth is heavily reliant on its blockbuster drug, Dupixent, which continues to see robust sales growth and label expansions. However, this concentration presents a significant risk ahead of its potential loss of exclusivity post-2031.
  While Sanofi boasts a strong dividend profile and an attractive valuation relative to peers, the company faces challenges including recent pipeline setbacks, increasing competition, and persistent drug pricing pressures in key markets.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul>
 <li>
<a href="https://smartkarma.com/entities/sanofi">Sanofi</a> is strategically repositioning itself as a pure-play biopharma company, focusing on high-growth areas like immunology and vaccines, underscored by the planned separation of its Consumer Healthcare business.</li>
 <li>The company's growth is heavily reliant on its blockbuster drug, Dupixent, which continues to see strong sales growth and label expansion, but this concentration also represents a significant risk pending its patent expiration around 2031.</li>
 <li>Management is actively pursuing a 'Play to Win' strategy, increasing R&amp;D investment, leveraging AI for drug discovery, and pursuing bolt-on acquisitions to strengthen its pipeline and mitigate future patent cliffs.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Sanofi is strategically repositioning itself as a pure-play biopharma company, focusing on high-growth areas like immunology and vaccines, underscored by the planned separation of its Consumer Healthcare business.
  The company's growth is heavily reliant on its blockbuster drug, Dupixent, which continues to see strong sales growth and label expansion, but this concentration also represents a significant risk pending its patent expiration around 2031.
  Management is actively pursuing a 'Play to Win' strategy, increasing R&amp;D investment, leveraging AI for drug discovery, and pursuing bolt-on acquisitions to strengthen its pipeline and mitigate future patent cliffs.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.</li>
<li>In terms of quantity and quality of innovations <a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US)</a>  and <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna (MRNA US)</a>  are best positioned. Among private companies Senda Biosciences screened well. </li>
<li>Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.</li>
</ul>


In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.
In terms of quantity and quality of innovations Alnylam Pharmaceuticals (ALNY US)  and Moderna (MRNA US)  are best positioned. Among private companies Senda Biosciences screened well. 
Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.


Who Are Leading the Charge in the RNAissance of Medicine

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

France

Sanofi operates as a pharmaceutical company. The Company manufactures prescription pharmaceuticals and vaccines. Sanofi also develops cardiovascular, thrombosis, metabolic disorder, central nervous system, and oncology medicines and drugs. Sanofi serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sanofi (SAN FP)

Sanofi Acquisition Of Regeneron: Could Dupixent & An $8 Billion Alliance Spark A Bigger Deal?

Sanofi has moved materially closer to Regeneron Pharmaceuticals (NASDAQ), although there is currently no disclosed takeover proposal or confirmed...

Baptista Research

Primer: Sanofi ADR (SNY US) - Aug 2026

Sanofi is strategically repositioning itself as a pure-play biopharmaceutical company, focusing on high-growth areas like immunology and...

αSK Primers

Primer: Sanofi (SAN FP) - Aug 2026

Sanofi is strategically repositioning itself as a pure-play biopharma company, focusing on high-growth areas like immunology and vaccines,...

αSK Primers

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)